It is perhaps an understatement to propose that Bexis, a co-founder of this blog in 2006, did so with a clear purpose in mind: to assist medical device and pharmaceutical manufacturers, entities that often find themselves at the sharp end of the litigation stick in our lawsuit-prone nation. This blog has evolved into a valuable conduit of information for colleagues in the drug and defense bars, with Bexis frequently identifying — or even creating — novel legal issues and concepts. These ideas are then disseminated to the point where they get interwoven into the legal fabric of our times.
Over-the-counter (OTC) drugs, often forgotten in such discussions, deserve the same degree of rigorous analysis to comprehend their complex legalities. Central to this is the concept of preemption, a critical aspect to comprehend when discussing the interplay between federal and state authority over such drugs. Preemption refers to the scenario where federal law supersedes state law.
OTC drugs inhabit a peculiar space in U.S. law, straddling the line between prescription and non-prescription consumer goods. This unique position has often meant that the legal issues surrounding these have been litigated less than their prescription counterparts. However, the jurisprudence that does exist on this issue suggests some fascinating and oft-debated trends in preemption.
Through an examination of case law by Reed Smith, this blog post delves into these issues with robust legal reasoning and reliable granular detail. This serves to illustrate how the application of various aspects of preemption shapes the landscape of OTC drugs law.
For those immersed in the pharmaceutical industry, this piece supported by Reed Smith, provides a comprehensive understanding of an often complex yet under-discussed topic. It further fuels the ongoing debate over the role of federal vs. state authority in the regulation of over-the-counter drugs.